Lawrence Traylor

Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering.

Cooley advised LegalZoom, a leading online platform for business formation, on its upsized follow-on public offering at $161 million.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised the underwriters in Arcutis Biotherapeutics’ $172.5 million follow-on offering of 8,625,000 shares of common stock at a public offering price of $20.00 per share. Arcutis is a biopharmaceutical company developing and commercializing innovative treatments for immuno-dermatological diseases. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.